[
{"protocolSection":{"identificationModule":{"nctId":"NCT02658019","orgStudyIdInfo":{"id":"20151049"},"organization":{"fullName":"University of Miami","class":"OTHER"},"briefTitle":"Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma","officialTitle":"Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)"},"statusModule":{"statusVerifiedDate":"2020-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-05-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-11-10","type":"ACTUAL"},"completionDateStruct":{"date":"2019-12-17","type":"ACTUAL"},"studyFirstSubmitDate":"2016-01-14","studyFirstSubmitQcDate":"2016-01-15","studyFirstPostDateStruct":{"date":"2016-01-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2020-09-21","resultsFirstSubmitQcDate":"2020-10-20","resultsFirstPostDateStruct":{"date":"2020-11-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-10-20","lastUpdatePostDateStruct":{"date":"2020-11-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Lynn Feun, MD","investigatorTitle":"Professor","investigatorAffiliation":"University of Miami"},"leadSponsor":{"name":"Lynn Feun, MD","class":"OTHER"},"collaborators":[{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced, unresectable hepatocellular carcinoma. The primary objective is to assess its therapeutic efficacy in patients with unresectable hepatocellular carcinoma (HCC)."},"conditionsModule":{"conditions":["Hepatocellular Carcinoma"],"keywords":["Hepatocellular Carcinoma","Advanced Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":29,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pembrolizumab in Advanced HCC","type":"EXPERIMENTAL","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.","interventionNames":["Drug: Pembrolizumab"]}],"interventions":[{"type":"DRUG","name":"Pembrolizumab","interventionMappedName":[],"description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.","armGroupLabels":["Pembrolizumab in Advanced HCC"],"otherNames":["Keytruda","MK-3475"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Disease Control Rate (DCR) in Study Participants","description":"Disease control rate (DCR) will be calculated per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, as the percentage of patients with best overall response to protocol therapy of either complete response (CR), partial response (PR) or stable disease (SD) that is maintained for at least 8 weeks.\n\nPer Response Evaluation Criteria in Sold Tumors Criteria (RECISTv1.1)for target lesions and assessed by MRI or CT: Complete response(CR),Disappearance of all target lesions; Partial response(PR),\\>=30% decrease in sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","timeFrame":"8 weeks"},{"measure":"Number of Participants With Treatment-Related Adverse Events","description":"The safety of Pembrolizumab in HCC patients as measured by the incidence of treatment-related adverse events, including serious adverse events (SAEs), in study participants using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, per physician discretion. The number of participants experiencing toxicity attributed by treating physician as definitely, probably and possibly-related to study treatment will be reported.","timeFrame":"Up to 2 years"}],"secondaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"Progression-free survival (PFS) will be defined as the elapsed time from the first date of study treatment until documented disease progression (as per RECIST 1.1) or death from any cause, whichever is earlier. For patients who remain alive without progression, follow-up time will be censored at the date of last disease assessment .","timeFrame":"Up to 25 months"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) will be defined as the elapsed time from the enrollment to death from any cause. For surviving patients, follow-up will be censored at the date of last contact (or last date known to be alive).","timeFrame":"Up to 25 months"},{"measure":"Objective Response Rate (ORR)","description":"Objective response rate (ORR) will be defined as the percentage of the patients with a confirmed complete or partial response (CR or PR),by MRI or CT scan as per RECIST 1.1 criteria. Complete response (CR), Disappearance of all target lesions; Partial response (PR), \\>=30% decrease in sum of the longest diameter of target lesions; Overall response (OR) = (CR+PR.)Scans and assessments are performed every 9 weeks while on treatment up to 2 years if stable/responding, or up until time of disease progression.","timeFrame":"Up to 2 years"},{"measure":"Duration of Response (DoR)","description":"Duration of Response (DoR) will be defined as the elapsed time from documented tumor response to documented disease progression.","timeFrame":"Up to 3 Years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients must have diagnosis of advanced hepatocellular cancer (HCC) by one of the following:\n\n   * Histopathology\n   * Elevated serum alpha-fetoprotein (AFP) \\>400 ng/ml and findings on magnetic resonance imaging (MRI) or computed tomography (CT) scans characteristic of HCC\n   * Findings on triple phase MRI or CT scans characteristic of HCC in patients with cirrhosis and tumors at least 1 cm or greater, without a curative treatment option (transplant, resection, or ablation).\n2. Measurable disease as defined by RECIST v1.1 (provided in Section 14.0).\n3. Radiographic progression on previously treated areas (as defined by RECIST v1.1).\n4. Subject refusal for sorafenib treatment or intolerance to sorafenib are also allowed (intolerance is defined as ≥ 28 days of sorafenib (not necessarily consecutive) or ≥grade 3 toxicity due to sorafenib which does not resolve with appropriate supportive care).\n5. Patients should have failed at least one prior systemic therapy regimen which could include sorafenib. Patients may have progressed on sorafenib, been intolerant of, or refused sorafenib. Patients who are documented to refuse systemic chemotherapy or sorafenib are also eligible. No limit to prior systemic therapy. Prior locoregional therapy such as surgery, radiofrequency ablation or transarterial chemoembolization are also allowed, provided that progression has been documented after these therapies, and ≥4 weeks have elapsed since the last therapy; (these will not be counted as systemic therapy).\n6. Child-Pugh Classification with score ≤ 7 points. See Appendix G for criteria.\n7. Age ≥ 18 years\n8. Estimated life expectancy, in the judgement of the Investigator, of at least ≥ 12 weeks.\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. See Appendix C.\n10. Adequate bone marrow function as defined below:\n\n    * absolute neutrophil count (ANC) ≥ 1.2 x 10\\^9/L,\n    * platelets (PLT) ≥ 50 x 10\\^9/L\n11. Adequate liver function as defined below:\n\n    * serum bilirubin \\< 2 mg/dl\n    * Aspartate transaminase (AST/SGOT) ≤ 5 x upper limit of normal (ULN),\n    * Alanine transaminase (ALT/SGPT) ≤ 5 x ULN\n12. Adequate coagulation as defined by:\n\n    * serum prothrombin time (PT) ≤ 16 seconds\n13. Adequate renal function as defined by one of the following:\n\n    * serum Creatinine ≤ 1.5 x ULN OR\n    * (measured or calculated) Creatinine clearance ≥ 60 mL/min for patients with serum creatinine levels \\> 1.5 x ULN.\n14. Suitable venous access to allow for all study-related blood sampling.\n15. Female subject of childbearing potential (CBP) must have a negative urine or serum pregnancy within 3 days prior to receiving the first dose of study medication.\n16. Females of child bearing potential that are sexually active must agree to either practice 2 medically accepted highly effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 120 days after the last dose of study drug. See Appendix H for protocol-approved highly effective methods of contraceptive combinations. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year.\n17. Negative test for pregnancy is required of females of child-bearing potential; A female of child bearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:\n\n    * has not undergone a hysterectomy or bilateral oophorectomy; or\n    * has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months or 730 days).\n18. Conception while on treatment must be avoided\n19. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n20. Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n2. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 2 years prior to the first dose of trial treatment.\n3. Major surgical procedure within 28 days prior to enrollment. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\n4. Any unresolved toxicity \\> CTCAE grade 2 despite optimal care/support, from previous anti-cancer therapy, within 28 days prior to first dose of study drug. \\[Exceptions: Alopecia and ≤grade 2 neuropathy.\\]\n5. Prior therapy with an anti-Programmed Death (PD)-1, anti-PD-Ligand-(L)-1, or anti-PD-L2 agent.\n6. Receipt of anti-cancer monoclonal antibody within 4 weeks prior to first dose of study drug.\n7. Prior treatment with any other chemotherapy, radiotherapy, immunotherapy, or anticancer drug, agent or biologic within 4 weeks prior to first dose of study drug.\n8. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.\n9. Receipt of any other investigational agents for their cancer ≤4 weeks of the first dose of study treatment.\n10. Known history of active Bacillus Tuberculosis (TB).\n11. Known history of, or any evidence of active, non-infectious pneumonitis or has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.\n12. Known history of Human Immunodeficiency Virus (HIV), HIV-1/2 antibodies.\n13. Known hypersensitivity to pembrolizumab or any of its excipients.\n14. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. \\[Exception: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging, for at least 4 weeks prior to the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not apply to carcinomatous meningitis which is excluded regardless of clinical stability.\\]\n15. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial through 120 days after the last dose of trial treatment.\n16. Any uncontrolled, intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.\n17. Has a known additional malignancy that is progressing or requires active treatment. \\[Exception: Basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.\\]\n18. Any other serious medical or psychiatric illness/condition likely in the judgment of the Investigator(s) to interfere or limit compliance with study requirements/treatment.\n19. Treatment for active hepatitis C virus (HCV) within 60 days of study entry. \\[Note: Untreated HCV positive subjects are eligible, and if stable on pembrolizumab for 6 months after study entry, consideration may be given to starting anti-HCV therapy, at the discretion of the treating Investigator.\\]\n20. HCC patients with evidence of prior hepatitis B virus (HBV) must fulfill the following criteria in order to be eligible for the study: HBV viral load (VL) \\<100 IU/mL before study enrollment, and subjects with active HBV need to be on anti-HBV suppression ≥3 months, throughout treatment and for 6 months after.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Lynn Feun, MD","affiliation":"University of Miami","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University of Miami","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}}],"locations_nested":[{"facility":"University of Miami","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}}]},"referencesModule":{"references":[{"pmid":"31251403","type":"RESULT","citation":"Feun LG, Li YY, Wu C, Wangpaichitr M, Jones PD, Richman SP, Madrazo B, Kwon D, Garcia-Buitrago M, Martin P, Hosein PJ, Savaraj N. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer. 2019 Oct 15;125(20):3603-3614. doi: 10.1002/cncr.32339. Epub 2019 Jun 28."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"29"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"28"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"29"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"8"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"21"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"25"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"9"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"20"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"27"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Disease Control Rate (DCR) in Study Participants","description":"Disease control rate (DCR) will be calculated per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, as the percentage of patients with best overall response to protocol therapy of either complete response (CR), partial response (PR) or stable disease (SD) that is maintained for at least 8 weeks.\n\nPer Response Evaluation Criteria in Sold Tumors Criteria (RECISTv1.1)for target lesions and assessed by MRI or CT: Complete response(CR),Disappearance of all target lesions; Partial response(PR),\\>=30% decrease in sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"8 weeks","groups":[{"id":"OG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","lowerLimit":"27.5","upperLimit":"66.1"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Treatment-Related Adverse Events","description":"The safety of Pembrolizumab in HCC patients as measured by the incidence of treatment-related adverse events, including serious adverse events (SAEs), in study participants using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03, per physician discretion. The number of participants experiencing toxicity attributed by treating physician as definitely, probably and possibly-related to study treatment will be reported.","populationDescription":"One participant experienced two SAEs; one with attribution of possible relation, and the second with probable relation to study treatment.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"}]}],"classes":[{"title":"SAEs with Attribution of Definite Relation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"SAEs with Attribution of Possible relation","categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]},{"title":"SAEs with Attribution of Probable Relation","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"AEs with Attribution of Definite Relation","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"AEs with Attribution of Possible Relation","categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}]},{"title":"AEs with Attribution of Probable Relation","categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"Progression-free survival (PFS) will be defined as the elapsed time from the first date of study treatment until documented disease progression (as per RECIST 1.1) or death from any cause, whichever is earlier. For patients who remain alive without progression, follow-up time will be censored at the date of last disease assessment .","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 25 months","groups":[{"id":"OG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","lowerLimit":"2","upperLimit":"7"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) will be defined as the elapsed time from the enrollment to death from any cause. For surviving patients, follow-up will be censored at the date of last contact (or last date known to be alive).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to 25 months","groups":[{"id":"OG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","lowerLimit":"7","upperLimit":"19"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"Objective response rate (ORR) will be defined as the percentage of the patients with a confirmed complete or partial response (CR or PR),by MRI or CT scan as per RECIST 1.1 criteria. Complete response (CR), Disappearance of all target lesions; Partial response (PR), \\>=30% decrease in sum of the longest diameter of target lesions; Overall response (OR) = (CR+PR.)Scans and assessments are performed every 9 weeks while on treatment up to 2 years if stable/responding, or up until time of disease progression.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 2 years","groups":[{"id":"OG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","lowerLimit":"15.9","upperLimit":"52.4"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"Duration of Response (DoR) will be defined as the elapsed time from documented tumor response to documented disease progression.","populationDescription":"Median duration of response was not achieved for the participants by the end of study participation at the 3-year follow up visit.","reportingStatus":"POSTED","timeFrame":"Up to 3 Years","groups":[{"id":"OG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"25 months","description":"Only treatment-emergent adverse events and serious adverse events are reported for this protocol. A treatment-emergent adverse event and serious adverse events (TEAE) are defined as any event that begins or worsens after the start of protocol treatment with a treating physician attribution of definite, probable or possible relation to treatment. One participant experienced two SAEs; one with attribution of possible relation, and the second with probable relation to study treatment.","eventGroups":[{"id":"EG000","title":"Pembrolizumab in Advanced HCC","description":"Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.","deathsNumAffected":9,"deathsNumAtRisk":29,"seriousNumAffected":7,"seriousNumAtRisk":29,"otherNumAffected":28,"otherNumAtRisk":29}],"seriousEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Rhabdomyolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]}],"otherEvents":[{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":10,"numAtRisk":29}]},{"term":"Alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":2,"numAtRisk":29}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":3,"numAtRisk":29}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":29}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":9,"numAtRisk":29}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"CPK increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Creatinine increased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":9,"numAtRisk":29}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Edema limbs","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Endocrine disorders - Other","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Left Peri-orbital tenderness","organSystem":"Eye disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":29}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":29}]},{"term":"Flu like symptoms","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Gastric ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Edema","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Hyperkalemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":6,"numAtRisk":29}]},{"term":"Joint effusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Localized edema","organSystem":"General disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Bilateral Lower Limb Edema","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Muscle cramps","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Elbow tenderness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Knee pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":29}]},{"term":"Nail loss","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":29}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":29}]},{"term":"Oral dysesthesia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":29}]},{"term":"Papulopustular rash","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":29}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":5,"numAtRisk":29}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":29}]},{"term":"Rash acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":29}]},{"term":"Skin Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":29}]},{"term":"Nail Change","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Psoriasis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":29}]},{"term":"Seborrheic Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Seborrheic Keratosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"Skin and subcutaneous tissue disorders - Other","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":29}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":29}]},{"term":"White blood cell decreased","organSystem":"Investigations","sourceVocabulary":"CTCAE (4.03)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":29}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Lynn G. Feun, MD","organization":"University of Miami","email":"lfeun@med.miami.edu","phone":"305-243-6606"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-09-15","uploadDate":"2020-09-21T09:20","filename":"Prot_SAP_000.pdf","size":1009982}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2023-09-06","modelPredictions":{"bmiLimits":{"minBmi":0.00,"maxBmi":101.00}}},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000006528","term":"Carcinoma, Hepatocellular"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000000230","term":"Adenocarcinoma"},{"id":"D000008113","term":"Liver Neoplasms"},{"id":"D000004067","term":"Digestive System Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000004066","term":"Digestive System Diseases"},{"id":"D000008107","term":"Liver Diseases"}],"browseLeaves":[{"id":"M5224","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M9303","name":"Carcinoma, Hepatocellular","asFound":"Hepatocellular Carcinoma","relevance":"HIGH"},{"id":"M12010","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12005","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M3275","name":"Adenocarcinoma","relevance":"LOW"},{"id":"M10803","name":"Liver Neoplasms","relevance":"LOW"},{"id":"M6946","name":"Digestive System Neoplasms","relevance":"LOW"},{"id":"M8576","name":"Gastrointestinal Neoplasms","relevance":"LOW"},{"id":"M6945","name":"Digestive System Diseases","relevance":"LOW"},{"id":"M8573","name":"Gastrointestinal Diseases","relevance":"LOW"},{"id":"M10797","name":"Liver Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC06","name":"Digestive System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000582435","term":"Pembrolizumab"}],"ancestors":[{"id":"D000074322","term":"Antineoplastic Agents, Immunological"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000082082","term":"Immune Checkpoint Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M349349","name":"Pembrolizumab","asFound":"Open-label","relevance":"HIGH"},{"id":"M1346","name":"Antineoplastic Agents, Immunological","relevance":"LOW"},{"id":"M2343","name":"Immune Checkpoint Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true},
{"protocolSection":{"identificationModule":{"nctId":"NCT05986331","orgStudyIdInfo":{"id":"BCD-201-2"},"organization":{"fullName":"Biocad","class":"INDUSTRY"},"briefTitle":"Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma","officialTitle":"A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients With Unresectable or Metastatic Melanoma"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-07-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-07-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-02-13","studyFirstSubmitQcDate":"2023-08-01","studyFirstPostDateStruct":{"date":"2023-08-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-01","lastUpdatePostDateStruct":{"date":"2023-08-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biocad","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This clinical study is designed as a randomized, double-blind trial. Subjects with unresectable, metastatic, or recurrent skin melanoma will be randomized to one of the two study groups (BCD-201 group and Keytruda group) at a 1:1 ratio.\n\nThe goal of this study is to compare the efficacy and safety of BCD-201 and Keytruda as first-line therapy in subjects with unresectable, metastatic, or recurrent skin melanoma."},"conditionsModule":{"conditions":["Melanoma (Skin)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":366,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BCD-201 group","type":"EXPERIMENTAL","description":"BCD-201 200 mg as a 30-minute intravenous infusion once every 3 weeks","interventionNames":["Drug: BCD-201"]},{"label":"Keytruda","type":"ACTIVE_COMPARATOR","description":"Keytruda 200 mg as a 30-minute intravenous infusion once every 3 weeks","interventionNames":["Drug: Keytruda"]}],"interventions":[{"type":"DRUG","name":"BCD-201","interventionMappedName":[],"description":"up to 8 treatment cycles","armGroupLabels":["BCD-201 group"],"otherNames":["Pembrolizumab"]},{"type":"DRUG","name":"Keytruda","interventionMappedName":[],"description":"up to 8 treatment cycles","armGroupLabels":["Keytruda"],"otherNames":["pembrolizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To compare the overall response rate (ORR) in the BCD-201 group and the Keytruda group","description":"ORR according to RECIST 1.1","timeFrame":"24 weeks of treatment"}],"secondaryOutcomes":[{"measure":"To compare the ORR according to iRECIST in the BCD-201 group and the Keytruda group","description":"ORR according to iRECIST","timeFrame":"every 12 weeks up to 2 years"},{"measure":"To compare the duration of response in the BCD-201 group and the Keytruda group","description":"Duration of response will be calculated from the moment of registration of response till event (progression or death)","timeFrame":"up to 2 years"},{"measure":"To compare the time to response according to RECIST 1.1 and iRECIST in the BCD-201 group and the Keytruda group","description":"time to response will be calculated from the randomization date","timeFrame":"every 12 weeks up to 2 years"},{"measure":"To compare the disease control rate in the BCD-201 group and the Keytruda group","description":"The percentage of the participants who have a Complete Response, a Partial Response or a Stable DIsease","timeFrame":"up to 2 years"},{"measure":"To compare the progression-free survival (PFS) per RECIST 1.1 and iRECIST in the BCD-201 group and the Keytruda group","description":"The time from the date of randomization until progression of disease according to RECIST 1.1 / iRECIST criteria or death","timeFrame":"up to 2 years"},{"measure":"To compare the overall survival in the BCD-201 group and the Keytruda group","description":"The time from the date of randomization until death","timeFrame":"up to 2 years"},{"measure":"To compare the incidence of Treatment-Emergent Adverse Events (Safety profiles of BCD-201 and Keytruda)","description":"Presence of any adverse events (AEs), presence of adverse reactions (ARs), presence of serious adverse reactions (SARs), presence of severe ARs (grade 3 or higher severity according to CTCAE v.5.0), presence of ARs leading to discontinuation of study therapy, presence of immune-mediated AEs","timeFrame":"through study completion, an average of 2 years."},{"measure":"Area under the concentration-time curve (AUC(0-504))","description":"Area under the plasma concentration versus time curve in the time interval from 0 to 504 hours","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"AUC(0-∞)","description":"Area under the plasma concentration versus time curve in the time interval from 0 to time infinity","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Peak Plasma Concentration (Cmax)","description":"maximum concentration of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Time to maximum concentration (Tmax)","description":"time to maximum concentration of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Elimination rate constant (kel)","description":"kel of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Total clearance (Cl)","description":"Cl of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Steady-state volume of distribution of the drug substance (Vd)","description":"Vd of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Half-life period (T1/2)","description":"T1/2 of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"Concentrations at the end of each infusion (CEOI)","description":"concentrations at the end of each infusion of pembrolizumab","timeFrame":"up to 24 weeks of the double-blind treatment period"},{"measure":"To compare the immunogenicity of BCD-201 and Keytruda.","description":"Development of binding and neutralizing antibodies to pembrolizumab","timeFrame":"pre-dose to day169 of the double-blind treatment period, 8 timepoints"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent;\n* Histologically confirmed melanoma;\n* Tumor first detected at the stage of advanced unresectable or metastatic disease, or disease progressing during or recurring after previous radical therapy;\n* ECOG score 0-1;\n* At least one measurable lesion according to RECIST 1.1;\n* Laboratory test results consistent with adequate functioning of systems and organs;\n* Willingness of men and women of childbearing potential to use highly effective contraceptive methods from the signing of the informed consent form, throughout the study and for 6 months after the administration of the last product dose.\n\nExclusion Criteria:\n\n* Indications for radical therapy (surgery, radiation therapy);\n* Uveal, ocular or mucosal melanoma;\n* Active CNS metastases and/or carcinomatous meningitis;\n* Subjects with severe concomitant disorders, life-threatening acute complications of the primary disease;\n* Concomitant diseases and/or conditions that significantly increase the risk of AEs during the study;\n* Active, known or suspected autoimmune disorders (subjects with type 1 diabetes mellitus or hypothyroidism requiring only hormone-replacement therapy and those with skin disorders \\[vitiligo, alopecia, or psoriasis\\] not requiring systemic therapy are eligible to participate);\n* The need for therapy with glucocorticoids or any other drugs with immunosuppressive effects within 14 days prior to randomization;\n* History of (non-infectious) pneumonitis requiring glucocorticoid therapy or pneumonitis at the time of screening;\n* Hypersensitivity or allergy to any of the pembrolizumab product components;\n* Pregnancy or breastfeeding, as well as intention to become pregnant or father a child during the study period.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Vladimir Chistiakov","role":"CONTACT","phone":"+7 (812) 380 49 34","email":"chistiakov@biocad.ru"}],"locations":[{"facility":"Budgetary healthcare institution of the Omsk region \"Clinical oncological dispensary\"","status":"ACTIVE_NOT_RECRUITING","city":"Omsk","country":"Russian Federation","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"\"Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)\"","status":"RECRUITING","city":"Saint Petersburg","country":"Russian Federation","contacts":[{"name":"Vladimir Moiseyenko","role":"CONTACT","email":"moiseyenkov@gmail.com"}],"geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Federal State Budgetary Educational Institution of Higher Education \"Saint Petersburg State University\"","status":"ACTIVE_NOT_RECRUITING","city":"Saint Petersburg","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}}],"locations_nested":[{"facility":"Budgetary healthcare institution of the Omsk region \"Clinical oncological dispensary\"","status":"ACTIVE_NOT_RECRUITING","city":"Omsk","country":"Russian Federation","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"\"Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)\"","status":"RECRUITING","city":"Saint Petersburg","country":"Russian Federation","contacts":[{"name":"Vladimir Moiseyenko","role":"CONTACT","email":"moiseyenkov@gmail.com"}],"geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Federal State Budgetary Educational Institution of Higher Education \"Saint Petersburg State University\"","status":"ACTIVE_NOT_RECRUITING","city":"Saint Petersburg","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2023-09-06","modelPredictions":{"bmiLimits":{"minBmi":0.00,"maxBmi":101.00}}},"conditionBrowseModule":{"meshes":[{"id":"D000008545","term":"Melanoma"}],"ancestors":[{"id":"D000018358","term":"Neuroendocrine Tumors"},{"id":"D000017599","term":"Neuroectodermal Tumors"},{"id":"D000009373","term":"Neoplasms, Germ Cell and Embryonal"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000009380","term":"Neoplasms, Nerve Tissue"},{"id":"D000018326","term":"Nevi and Melanomas"}],"browseLeaves":[{"id":"M11218","name":"Melanoma","asFound":"Melanoma","relevance":"HIGH"},{"id":"M20185","name":"Neuroendocrine Tumors","relevance":"LOW"},{"id":"M19535","name":"Neuroectodermal Tumors","relevance":"LOW"},{"id":"M20078","name":"Neuroectodermal Tumors, Primitive","relevance":"LOW"},{"id":"M12008","name":"Neoplasms, Germ Cell and Embryonal","relevance":"LOW"},{"id":"M12005","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M12015","name":"Neoplasms, Nerve Tissue","relevance":"LOW"},{"id":"M12136","name":"Nevus","relevance":"LOW"},{"id":"M12138","name":"Nevus, Pigmented","relevance":"LOW"},{"id":"M20160","name":"Nevi and Melanomas","relevance":"LOW"},{"id":"T4091","name":"Neuroendocrine Tumor","relevance":"LOW"},{"id":"T4092","name":"Neuroepithelioma","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000582435","term":"Pembrolizumab"}],"ancestors":[{"id":"D000074322","term":"Antineoplastic Agents, Immunological"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000082082","term":"Immune Checkpoint Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M349349","name":"Pembrolizumab","asFound":"Open-label","relevance":"HIGH"},{"id":"M1346","name":"Antineoplastic Agents, Immunological","relevance":"LOW"},{"id":"M2343","name":"Immune Checkpoint Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT04098068","orgStudyIdInfo":{"id":"J1365 (Cohort D)"},"secondaryIdInfos":[{"id":"MK-3475-016","type":"OTHER","domain":"Merck"},{"id":"NA_00085756","type":"OTHER","domain":"JHM IRB"}],"organization":{"fullName":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","class":"OTHER"},"briefTitle":"Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)","officialTitle":"Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-01-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-05-15","type":"ACTUAL"},"completionDateStruct":{"date":"2024-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-09-19","studyFirstSubmitQcDate":"2019-09-19","studyFirstPostDateStruct":{"date":"2019-09-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-03-30","resultsFirstSubmitQcDate":"2023-04-25","resultsFirstPostDateStruct":{"date":"2023-05-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-01","lastUpdatePostDateStruct":{"date":"2023-09-06","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","class":"OTHER"},"collaborators":[{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will be looking at whether MK-3475 (pembrolizumab) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite Unstable) negative cancer with a mutator phenotype."},"conditionsModule":{"conditions":["High Tumor Mutation Burden","High TMB (Tumor Mutation Burden)","MSS (Microsatellite Stable)"],"keywords":["Mutation load","Tumor mutation load","Mutation burden","Tumor mutation burden (TMB)","Hypermutation","MSI Negative with Mutator Phenotype (High Tumor Mutation Burden)","TMB (Tumor Mutation Burden)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":12,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MSI (Microsatellite Unstable) Negative with Mutator Phenotype","type":"EXPERIMENTAL","interventionNames":["Drug: MK-3475"]}],"interventions":[{"type":"DRUG","name":"MK-3475","interventionMappedName":[],"description":"MK-3475 (pembrolizumab) 200 mg flat dose every 21 days","armGroupLabels":["MSI (Microsatellite Unstable) Negative with Mutator Phenotype"],"otherNames":["Pembrolizumab"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype","description":"Objective Response Rate (ORR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions.","timeFrame":"2 years"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.","timeFrame":"4 years"},{"measure":"Progression-Free Survival (PFS) in Patients Using RECIST 1.1(Response Evaluation Criteria In Solid Tumors)","description":"PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 6 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \\>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.","timeFrame":"4 years"},{"measure":"Disease Control Rate (DCR)","description":"Disease Control Rate (DCR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions, progressive disease (PD) is \\>20% increase in sum of diameters of target lesions, stable disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions.","timeFrame":"2 years"},{"measure":"Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity","description":"When calculating the incidence of AEs, each adverse event (AE) (as defined by NCI CTCAE v4.03) will be counted only once for a given subject.","timeFrame":"28 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with microsatellite stable tumor and a tumor mutation burden (TMB) level measured at \\> 20 mutations per megabase pairs (MB)\n* Have measurable disease\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1\n* Adequate organ function as defined by study-specified laboratory tests\n* Must use acceptable form of birth control through the study and for 28 days after final dose of study drug\n* Signed informed consent form\n* Willing and able to comply with study procedures\n* Agree to have a biopsy of their cancer\n* Patients with colon cancer must have received at least two prior cancer therapy regimens.\n* Patients with other cancer types must have received at least one prior cancer therapy\n* Progressive disease\n\nExclusion Criteria:\n\n* Patients with uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements.\n* Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior to the first dose of study drug\n* Patients who have had radiation within 2 weeks prior to the first dose of study drug\n* Patients who have undergone major surgery within 4 weeks of dosing of investigational agent\n* Patients who have received another investigational product or investigational device within 4 weeks prior to receiving study drug\n* Patients who have received any of the following concomitant therapy: Interleukin-2 (IL-2), interferon, or other non-study immunotherapy regimens, immunosuppressive agents, other investigational therapies or chronic use of systemic corticosteroids within one week prior to first dose of study drug\n* Patients who have received a live vaccine within 4 weeks prior to or after any dose of MK-3475 (exception: inactivated flu vaccines)\n* Patients who have received growth factors, including but not limited to granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, etc. within 2 weeks of study drug administration\n* Patient who have had prior treatment with anti-PD-1 (anti-programmed cell death protein 1), anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4 antibodies\n* Patients with history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis, central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin.\n* Patients who have known history of infection with HIV, hepatitis B, or hepatitis C\n* Patients with evidence of interstitial lung disease\n* Systemically active steroid use\n* Patients on home oxygen\n* Patients with oxygen saturation of \\<92% on room air by pulse oximetry\n* Pregnant or lactating\n* Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures\n* Patient with known active central nervous system metastases and/or carcinomatous meningitis.\n* Patients with primary brain tumors.\n* Requires any other form of systemic or localized antineoplastic therapy while on study\n* Has any tissue or organ allograft\n* Patients with history of allogeneic hematopoeitic stem cell transplant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dung Le, MD","affiliation":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"Maryland","zip":"21231","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}}],"locations_nested":[{"facility":"Sidney Kimmel Comprehensive Cancer Center","city":"Baltimore","state":"Maryland","zip":"21231","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Memorial Sloan Kettering Cancer Center","city":"New York","state":"New York","zip":"10065","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Ohio State University","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"MSI (Microsatellite Unstable) Negative With Mutator Phenotype","description":"MK-3475 (pembrolizumab): MK-3475 200 mg flat dose every 21 days"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Disease Progression","reasons":[{"groupId":"FG000","numSubjects":"7"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"}]},{"type":"New Cancer Diagnosis","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"MSI (Microsatellite Unstable) Negative With Mutator Phenotype","description":"MK-3475 (pembrolizumab): MK-3475 200 mg flat dose every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"6"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype","description":"Objective Response Rate (ORR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions.","populationDescription":"Only 11/12 were evaluable for this outcome","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"2 years","groups":[{"id":"OG000","title":"MSI (Microsatellite Unstable) Negative With Mutator Phenotype","description":"MK-3475 (pembrolizumab): MK-3475 200 mg flat dose every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS will be measured from date of first dose until death or end of follow-up (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2024-02","timeFrame":"4 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Progression-Free Survival (PFS) in Patients Using RECIST 1.1(Response Evaluation Criteria In Solid Tumors)","description":"PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 6 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \\>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.","reportingStatus":"NOT_POSTED","anticipatedPostingDate":"2024-02","timeFrame":"4 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Disease Control Rate (DCR)","description":"Disease Control Rate (DCR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions, progressive disease (PD) is \\>20% increase in sum of diameters of target lesions, stable disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions.","populationDescription":"Only 11/12 were evaluable for this outcome","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"2 years","groups":[{"id":"OG000","title":"MSI (Microsatellite Unstable) Negative With Mutator Phenotype","description":"MK-3475 (pembrolizumab): MK-3475 200 mg flat dose every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity","description":"When calculating the incidence of AEs, each adverse event (AE) (as defined by NCI CTCAE v4.03) will be counted only once for a given subject.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"28 months","groups":[{"id":"OG000","title":"MSI (Microsatellite Unstable) Negative With Mutator Phenotype","description":"MK-3475 (pembrolizumab): MK-3475 200 mg flat dose every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Serious and Other Adverse Events assessed for up to 28 months. All-Cause Mortality assessed for up to 51 months.","eventGroups":[{"id":"EG000","title":"MSI (Microsatellite Unstable) Negative With Mutator Phenotype","description":"MK-3475 (pembrolizumab): MK-3475 200 mg flat dose every 21 days","deathsNumAffected":4,"deathsNumAtRisk":12,"seriousNumAffected":6,"seriousNumAtRisk":12,"otherNumAffected":5,"otherNumAtRisk":12}],"seriousEvents":[{"term":"Congestive heart failure","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Disease progression","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Opioid use disorder","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Plasma cell myeloma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Diffuse large B cell lymphoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":12}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":12}]},{"term":"Anorexia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":12}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Cellulitis","organSystem":"Immune system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Chills","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Conjunctival erythema","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":12}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"COVID infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dehydration","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Dental pain","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Depression","organSystem":"Psychiatric disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Diabetes mellitus","organSystem":"Endocrine disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":12}]},{"term":"Dry eye","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Edema","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":12}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Esophageal dysmotility","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Esophagitis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Fatigue","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":12}]},{"term":"Fever","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Ganglion cyst","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Gastroesophageal reflux","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Headache","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Hernia","organSystem":"Injury, poisoning and procedural complications","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hyperbilirubinemia","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hyperglycemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypoalbuminemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Hyponatremia","organSystem":"Metabolism and nutrition disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypotension","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":12}]},{"term":"Metrorrhagia","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":12}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":12}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":12}]},{"term":"Nocturia","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Oral thrush","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":12}]},{"term":"Pelvic pain","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Platelet count decreased","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Pruritis","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":12}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":12}]},{"term":"Sinus pain","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":12}]},{"term":"Small bowel obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Sweating","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Thromboembolic event","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Upper respiratory infection","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Urinary tract pain","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":12}]},{"term":"Vaginal hemorrhage","organSystem":"Reproductive system and breast disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":3,"numAtRisk":12}]},{"term":"Watering eyes","organSystem":"Eye disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":12}]},{"term":"Weight loss","organSystem":"Investigations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":12}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Dung Le, MD","organization":"Sidney Kimmel Comprehensive Center at Johns Hopkins University","email":"dle@jhmi.edu","phone":"443-287-0002"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2020-08-07","uploadDate":"2023-03-22T13:23","filename":"Prot_SAP_000.pdf","size":937953}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2023-09-06","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-04-21","type":"ACTUAL"}}},"modelPredictions":{"bmiLimits":{"minBmi":0.00,"maxBmi":101.00}}},"conditionBrowseModule":{"meshes":[{"id":"D000009369","term":"Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"C000582435","term":"Pembrolizumab"}],"ancestors":[{"id":"D000074322","term":"Antineoplastic Agents, Immunological"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000082082","term":"Immune Checkpoint Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M349349","name":"Pembrolizumab","asFound":"Open-label","relevance":"HIGH"},{"id":"M1346","name":"Antineoplastic Agents, Immunological","relevance":"LOW"},{"id":"M2343","name":"Immune Checkpoint Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}
]